

Supplemental Table S4. Risk Factors Related to the Risk PTC and PTMC and the Performance (AUC)^a in Each Logistic Regression Model

Model	Models using creatinine-adjusted UICs, $\mu\text{g/gCr}$		Models using unadjusted UICs, $\mu\text{g/L}$	
	PTC	PTMC	PTC	PTMC
Model 1				
UIC ^b	15.00 (7.74–29.06)	6.98 (4.37–11.15)	18.63 (9.87–35.15)	8.83 (5.60–13.90)
Model 2				
UIC ^b	16.56 (8.46–32.41)	7.84 (4.84–12.81)	18.97 (9.98–36.05)	9.05 (5.66–14.46)
TSH, $\mu\text{IU/mL}^c$	1.38 (0.93–2.04)	1.55 (1.06–2.26)	1.33 (0.89–1.99)	1.50 (1.02–2.20)
Free T4, ng/dL^c	2.85 (1.95–4.17)	3.84 (2.64–5.57)	2.39 (1.62–3.52)	3.25 (2.22–4.75)
Model 3				
UIC ^b	19.16 (9.31–39.42)	8.41 (4.81–14.71)	19.89 (10.08–39.28)	9.10 (5.34–15.50)
TSH, $\mu\text{IU/mL}^c$	1.30 (0.83–2.01)	1.44 (0.93–2.24)	1.18 (0.75–1.84)	1.35 (0.86–2.11)
Free T4, ng/dL^c	2.50 (1.64–3.82)	3.74 (2.41–5.80)	2.27 (1.48–3.50)	3.54 (2.26–5.55)
Age	1.00 (0.98–1.02)	1.02 (0.99–1.04)	1.02 (0.99–1.04)	1.03 (1.01–1.06)
Female sex	0.94 (0.56–1.58)	0.71 (0.42–1.21)	0.71 (0.42–1.21)	0.54 (0.32–0.94)
Total energy intake	1.04 (0.98–1.08)	0.98 (0.95–1.04)	1.01 (0.99–1.01)	0.99 (0.98–1.01)
Education	6.70 (4.07–11.03)	11.04 (6.59–18.49)	6.76 (4.05–11.27)	10.94 (6.44–18.58)
Family history of cancer	1.27 (0.81–2.00)	1.84 (1.19–2.84)	1.21 (0.77–1.91)	1.94 (1.24–3.04)
Benign thyroid diseases	2.61 (1.03–6.61)	3.35 (1.42–7.90)	2.49 (0.96–6.48)	2.90 (1.22–6.92)
Dyslipidemia	4.70 (2.22–9.92)	5.54 (2.60–11.79)	4.86 (2.22–10.61)	6.54 (2.98–14.34)
AUC (95% CI) ^a				
Model 1 ^d	0.714 (0.688–0.740)	0.688 (0.659–0.717)	0.749 (0.722–0.777)	0.730 (0.701–0.759)
Model 2 ^d	0.785 (0.752–0.818)	0.776 (0.743–0.810)	0.801 (0.769–0.832)	0.796 (0.764–0.828)
Model 3 ^d	0.850 (0.821–0.880)	0.858 (0.829–0.885)	0.858 (0.830–0.887)	0.867 (0.840–0.894)

Values are expressed as odds ratio (95% confidence interval).

PTC, papillary thyroid cancer; PTMC, papillary thyroid microcarcinoma; AUC, area under the receiver operating characteristic (ROC) curve; UIC, urinary iodine concentration; TSH, thyroid stimulating hormone; T4, thyroxine.

^aThe performance of the model was estimated by the AUC; ^bCreatinine-adjusted UIC ($\geq 220 \mu\text{g/gCr}$ vs. $85\text{--}219 \mu\text{g/gCr}$), unadjusted UIC ($\geq 300 \mu\text{g/L}$ vs. $100\text{--}299 \mu\text{g/L}$); ^cTSH ($\geq 2.16 \mu\text{IU/mL}$ vs. $0.4\text{--}2.15 \mu\text{IU/mL}$), free T4 ($\geq 1.25 \text{ng/dL}$ vs. $0.70\text{--}1.24 \text{ng/dL}$); ^dAll of the *P* values for the AUC difference between Model 1 and 2, between Model 2 and 3, and between Model 2 and 3 were statistically significant ($P < 0.01$). Models with creatinine-adjusted UICs were not statistically different from those with unadjusted UICs.